Skip to content

Study · Systematic review · n = 57,911 · 2024

3 results

Evaluating the safety profile of semaglutide: an updated meta-analysis.

Rivera FB, Arias-Aguirre E, Aguirre Z, Ybañez MJC, Rubia JMM, Galang DJ, Lumbang GN, Ruyeras JMMJ, Magalong JV, Pine PL, Amigo JAC, Ansay MFM, Zelenkov N, Thomas SS, Vijayaraghavan K

Current medical research and opinion27 Jul 2024Cited by 11 (Europe PMC)

PMID39046272 (opens in a new tab)DOI10.1080/03007995.2024.2383731 (opens in a new tab)PepBankPUB-39046272
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In a meta-analysis of randomized trials, the adverse events associated with semaglutide were gastrointestinal, including nausea.

    In plain wordsIn a pooled analysis of trials, nausea was one of the side effects linked to semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseNausea
    Study

    n = 57,911

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The meta-analysis revealed that the adverse event associated with semaglutide is gastrointestinal in nature (nausea and vomiting).
    2 context sentences
    Summary · context
    Randomized controlled trials assessing the safety of semaglutide vs. placebo, with specified treatment durations were identified.
    Summary · context
    A total of 23 studies met the inclusion criteria with a combined sample size of 57,911 participants.
  2. 02HumanSystematic reviewSafety outcome

    In a meta-analysis of randomized trials, the adverse events associated with semaglutide were gastrointestinal, including vomiting.

    In plain wordsIn a pooled analysis of trials, vomiting was one of the side effects linked to semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseVomiting
    Study

    n = 57,911

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The meta-analysis revealed that the adverse event associated with semaglutide is gastrointestinal in nature (nausea and vomiting).
    2 context sentences
    Summary · context
    Randomized controlled trials assessing the safety of semaglutide vs. placebo, with specified treatment durations were identified.
    Summary · context
    A total of 23 studies met the inclusion criteria with a combined sample size of 57,911 participants.
  3. 03HumanSystematic reviewSafety outcome

    In a meta-analysis of randomized trials, no significant differences were observed between semaglutide and comparator groups.

    In plain wordsIn a pooled analysis of trials, safety outcomes with semaglutide did not differ significantly from comparator groups.

    Peptide
    Semaglutide
    Outcome
    No significant changeSafety outcomes versus comparator groups
    Study

    n = 57,911

    Comparator
    Comparator groups
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant differences were observed between semaglutide and comparator groups.
    2 context sentences
    Summary · context
    Randomized controlled trials assessing the safety of semaglutide vs. placebo, with specified treatment durations were identified.
    Summary · context
    A total of 23 studies met the inclusion criteria with a combined sample size of 57,911 participants.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.